| piclidenoson (CF101) / Can-Fite |
2021-002009-85: Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Pilot Trial Пиклиденозон за лечение на COVID-19 – Рандомизирано, двойно-заслепено, плацебо-контролирано пилотно изпитване. |
|
|
| Not yet recruiting | 2 | 100 | Europe | Piclidenoson, CF101, Tablet | Can-Fite BioPharma, Ltd., CanFite BioPharma Ltd. | COVID-19 КОВИД-19, COVID-19 КОВИД-19, Diseases [C] - Virus Diseases [C02] | | | | |
| namodenoson (CF102) / Can-Fite |
2021-005286-41: Clinical trial in patients with Advanced Hepatocellular Carcinoma and Child Pugh Class B7 cirrhosis. Клинично изпитване при пациенти с с авансирал хепатоцелуларен карцином с Child-Pugh цироза клас Б7 |
|
|
| Not yet recruiting | 3 | 471 | Europe | CF102, CF102, Capsule | CanFite BioPharma Ltd., CanFite BioPharma Ltd. | Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis Авансирал хепатоцелуларен карцином с Child-Pugh цироза клас В7, Liver cancer Чернодробен карцином, Diseases [C] - Cancer [C04] | | | | |
LIVERATION, NCT05201404: Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
|
|
| Recruiting | 3 | 471 | Europe, US, RoW | Namodenoson, CF102, Placebo, Inactive control | Can-Fite BioPharma | Hepatocellular Carcinoma, Cirrhosis | 02/25 | 10/25 | | |
| Not yet recruiting | 2 | 20 | RoW | Namodenoson 25mg, CF102 | Can-Fite BioPharma | Pancreatic Adenocarcinoma, Pancreatic Cancer | 07/26 | 12/26 | | |
| Recruiting | 2 | 114 | Europe, RoW | Namodenoson, CF102, Placebo, Inactive control | Can-Fite BioPharma, CanFite BioPharma Ltd. | NASH - Nonalcoholic Steatohepatitis | 04/25 | 10/25 | | |
| Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon |
2018-001546-33: The effects of switching one drug, used to treat either Ulcerative Colitis (UC) or Crohn’s disease (CD) to another drug, also used to treat UC or Crohn’s disease |
|
|
| Not yet recruiting | 4 | 200 | Europe | Flixabi, Infusion, Flixabi | University Southampton Hospital NHS Foundation Trust, Biogen Idec Ltd | Inflammatory Bowel Disease in particular Crohn's Disease and Ulcerative Colitis, Crohn’s Disease: Inflammation of the digestive system or gutUlcerative Colitis: Inflammation and ulceration of the large bowel, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Enrolling by invitation | 4 | 148 | Europe | Infliximab, Remicade, Flixabi, Inflectra, Remsima, Zessly, Adalimumab, Humira, AMGEVITA, Hulio, Hyrimoz, Idacio, Imraldi | University Medical Center Groningen, European Crohn´s and Colitis Organisation, Bühlmann Laboratories AG | Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative | 03/25 | 03/25 | | |
CAMEO, NCT05781152: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease |
|
|
| Recruiting | 4 | 900 | Canada, US | Anti-TNF therapy, Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio | Connecticut Children's Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emory University, Children's Hospital Medical Center, Cincinnati, University of North Carolina, Chapel Hill | Crohn Disease | 07/28 | 07/29 | | |
| Recruiting | 2/3 | 180 | US | RoadMAB, Infliximab, Avsola, Inflectra, Ixifi, Remicade, Renflexis | Children's Hospital Medical Center, Cincinnati, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Janssen Scientific Affairs, LLC | Crohn Disease | 03/27 | 03/27 | | |
NCT04305145: Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis |
|
|
| Recruiting | 2 | 42 | US | Infliximab, AVSOLA, Ixifi, Remicade, Renflexis, Methylprednisolone, Solu-Medrol, Duralone, Medralone, Medrol, M-Prednisol, Prednisone, Deltasone, Prednicot, predniSONE Intensol, Rayos, Sterapred, Sterapred DS | Massachusetts General Hospital, Dana-Farber Cancer Institute | Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event | 06/30 | 06/30 | | |
NCT05034536: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma |
|
|
| Recruiting | 2 | 36 | US | Pembrolizumab, Keytruda, Infliximab, AVSOLA, Ixifi, Remicade, Renflexis, Placebo, Relatlimab, Nivolumab | Massachusetts General Hospital, Massachusetts Institute of Technology | Metastatic Melanoma | 06/25 | 06/26 | | |
RUN-CD, NCT03108326: Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease |
|
|
| Recruiting | N/A | 900 | Europe | Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra | Ced Service GmbH | Crohn Disease | 03/23 | 03/23 | | |
NeuMRA, NCT04378621: Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients |
|
|
| Active, not recruiting | N/A | 212 | Europe | TNF-α inhibitor OR JAK inhibitor, TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz), Hand training, physiotherapy of hands | Vastra Gotaland Region | Rheumatoid Arthritis, Pain, Fatigue, Cognitive Decline, Depression, Brain Diseases, Hand Rheumatism | 09/25 | 09/25 | | |
| Cejemly (sugemalimab) / CStone Pharma |
| Completed | 3 | 381 | RoW | CS1001 monoclonal antibody, CS1001 placebo | CStone Pharmaceuticals | Non-Small Cell Lung Cancer Stage III | 04/23 | 04/23 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 479 | RoW | CS1001 monoclonal antibody, CS1001 placebo | CStone Pharmaceuticals | Non Small Cell Lung Cancer | 05/23 | 06/25 | | |
|
|
|
|
|
|
| Completed | 3 | 479 | RoW | CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin, Capecitabine | CStone Pharmaceuticals | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 07/23 | 09/23 | | |
|
|
| Completed | 3 | 540 | RoW | CS1001+ Fluorouracil+Cisplatin, Placebo+ Fluorouracil+Cisplatin | CStone Pharmaceuticals | Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | 10/22 | 10/22 | | |
|
|
NCT06617416: A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC |
|
|
| Not yet recruiting | 3 | 560 | RoW | Cadonilimab (AK104), Sugemalimab | Akeso | NSCLC (Non-small Cell Lung Cancer) | 10/26 | 12/28 | | |
NCT06031597: Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy |
|
|
| Not yet recruiting | 3 | 105 | NA | radiotherapy, Platinum-Based Drug, Cisplatin, Immunotherapy, Nivolumab, Atezolizumab, Durvalumab, Pembrolizumab, Tislelizumab, Sugemalimab, Sintilimab, Camrelizumab, Immunotherapeutic Agent | Zhejiang Cancer Hospital | Non-small Cell Lung Cancer Stage III | 12/25 | 12/25 | | |
NCT05700448: Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma |
|
|
| Not yet recruiting | 3 | 150 | NA | Sugemalimab, Placebo, Pegaspargase, Gemcitabine, Oxaliplatin | CStone Pharmaceuticals | Extranodal NK/T-cell Lymphoma | 11/27 | 11/28 | | |
SURPASS, NCT05623267: Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT |
|
|
| Recruiting | 2/3 | 346 | RoW | Sugemalimab, Placebo | Sun Yat-sen University | Limited Stage Small Cell Lung Cancer | 12/25 | 03/27 | | |
GEMSTONE-201, NCT03595657: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) |
|
|
| Completed | 2 | 80 | RoW | CS1001 | CStone Pharmaceuticals | Extranodal Natural Killer/T-Cell Lymphoma | 03/23 | 03/23 | | |
|
|
|
NCT05940532: A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC |
|
|
| Recruiting | 2 | 41 | RoW | Sugemalimab and Chemotherapy | Hunan Cancer Hospital | Carcinoma, Non-Small-Cell Lung | 01/25 | 12/26 | | |
SCS-Lung01, NCT06217757: Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC |
|
|
| Recruiting | 1/2 | 45 | RoW | Low-dose radiotherapy, LDRT, Etoposide, One of the standard chemotherapy regimens, Cisplatin, Sugemalimab, Programmed Death Ligand-1 (PD-L1) Inhibitor, Olaparib, poly ADP-ribose polymerase (PARP) inhibitor | Sichuan University | Lung Cancer, Extensive-stage Small-cell Lung Cancer | 06/26 | 03/27 | | |
NCT04472858: A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Donafenib, CS1001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd, CStone Pharmaceuticals | Advanced Solid Tumor | 12/23 | 12/23 | | |
NCT04421352: Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients |
|
|
| Completed | 1 | 11 | RoW | CS1001 | CStone Pharmaceuticals | Relapsed Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Recruiting | 1 | 9 | RoW | NK510, Tislelizumab，atezolizumab or sugemalimab | Base Therapeutics (Shanghai) Co., Ltd., The General Hospital of Eastern Theater Command | NSCLC | 07/24 | 07/24 | | |
ChiCTR2400079979: Phase I Study of Low-Dose Radiotherapy Plus Chemotherapy and Sugemalimab and Olaparib for First-Line Treatment of SLFN-11 positive Extensive Stage Small Cell Lung Cancer |
|
|
| Not yet recruiting | 1 | 45 | | Low-Dose Radiotherapy Plus Chemotherapy (Carboplatin and Etoposide)and Sugemalimab and Olaparib | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Sichuan Cancer Society | Small Cell Lung Cancer | | | | |
NCT05131438: An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) |
|
|
| No Longer Available | N/A | | US | sugemalimab | EQRx International, Inc. | Extranodal NK/T-cell Lymphoma | | | | |
